3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
9
Phase 2
8
Phase 1/2
5
Phase 3
2
Phase 2/3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Cyclophosphamide
26
Rituximab
17
Etoposide
16
Methotrexate
15
Dexamethasone
15
Cytarabine
15
Vincristine
14
Prednisone
11
Doxorubicin
11
Radiotherapy
10
blinatumomab
8
fludarabine
7
Mercaptopurine
7
Filgrastim
7
Daunorubicin
7
Asparaginase
7
pegaspargase
6
Granulocyte Colony-Stimulating Factor
6
Methylprednisolone
5
Drug Therapy
5
Dasatinib
5
venetoclax
4
prednylidene
4
etoposide phosphate
4
deltacortene
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Busulfan
4
Bendamustine Hydrochloride
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
ublituximab
×
Lymphoid
×
Clear all
NCT03801525
2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3
Terminated
277 enrolled
19 charts
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA